Fate of nanomedicines in the lungs

Current Opinion in Colloid and Interface Science

Volumn 16, Issue 3, 2011, Pages 246-254

  Todoroff, Julie ^a   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Alveolar macrophages; Mucociliary clearance; Nanoparticles; Proteins; Pulmonary drug delivery; Respiratory epithelia

Indexed keywords

AIR LIQUID INTERFACES; ALVEOLAR MACROPHAGES; BIOLOGICAL PROPERTIES; DOMINANT PATHWAYS; MUCOCILIARY CLEARANCE; NANOMEDICINES; PHYSICO-CHEMICALS; PROTEIN METABOLISM; PULMONARY DRUG DELIVERY; RECEPTOR-MEDIATED ENDOCYTOSIS; RESPIRATORY EPITHELIA; SYSTEMIC CIRCULATION; THERAPEUTIC PROTEIN;

DRUG DELIVERY; MACROPHAGES; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; NANOPARTICLES; PHASE INTERFACES; PROTEINS;

BIOLOGICAL ORGANS;

AFREZZA; DORNASE ALFA; IMMUNOGLOBULIN G; INSULIN; LIPOSOME; NANOPARTICLE; RECOMBINANT HUMAN INSULIN; TECHNOSPHERE; UNCLASSIFIED DRUG;

CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; LUNG; LUNG ALVEOLUS EPITHELIUM; MACROPHAGE; MUCOCILIARY CLEARANCE; NANOMEDICINE; PROTEIN METABOLISM; REVIEW;

EID: 79955962278     PISSN: 13590294     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cocis.2011.03.001     Document Type: Review

References (83)

1. Kewal K.J. Introduction. Handbook of nanomedicine 2008, 3.
2. Nimje N., Agarwal A., Saraogi G.K., Lariya N., Rai G., Agrawal H., et al. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target 2009, 17:777-787.
3. Schmidt S.R. Fusion-proteins as biopharmaceuticals-applications and challenges. Curr Opin Drug Discov Dev 2009, 12:284-295.
4. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10:1451-1458.
5. Ward E.S., Ober R.J. Multitasking by exploitation of intracellular transport functions: the many faces of FcRn. Adv Immunol 2009, 103:77-115.
6. http://www.ecompendium.be.
7. Bitonti A.J., Dumont J.A., Low S.C., Peters R.T., Kropp K.E., Palombella V.J., et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004, 101:9763-9768.
8. Meers P., Neville M., Malinin V., Scotto A.W., Sardaryan G., Kurumunda R., et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008, 61:859-868.
9. Parkes W.R. Morphology of the respiratory tract. Occupational lung disorders 1994, 1-17. third ed.
10. Crapo J.D., Barry B.E., Gehr P., Bachofen M., Weibel E.R. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 1982, 126:332-337.
11. Mercer R.R., Russell M.L., Roggli V.L., Crapo J.D. Cell number and distribution in human and rat airways. Am J Respir Cell Mol Biol 1994, 10:613-624.
12. Van der Schans C.P. Bronchial mucus transport. Respir Care 2007, 52:1150-1156.
13. Clunes M.T., Boucher R.C. Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder. Drug Discov Today Dis Mech 2007, 4:63-72.
14. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009, 61:158-171.
15. Bansil R., Turner B.S. Mucin structure, aggregation, physiological functions and biomedical applications. Curr Opin Colloid Interface Sci 2006, 11:164-170.
16. Bernhard W., Haslam P.L., Floros J. From birds to humans: new concepts on airways relative to alveolar surfactant. Am J Respir Cell Mol Biol 2004, 30:6-11.
17. Perez-Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim Biophys Acta 2008, 1778:1676-1695.
18. Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv 2010, 23:207-217.
19. Holt P.G., Strickland D.H., Wikstrom M.E., Jahnsen F.L. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008, 8:142-152.
20. Buhling F., Waldburg N., Reisenauer A., Heimburg A., Golpon H., Welte T. Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation. Eur Respir J 2004, 23:620-628.
21. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003, 200:448-464.
22. van der Velden V., Hulsmann A.R. Peptidases: structure, function and modulation of peptide-mediated effects in the human lung. Clin Exp Allergy 1999, 29:445-456.
23. Buhling F., Groneberg D., Welte T. Proteases and their role in chronic inflammatory lung diseases. Curr Drug Targets 2006, 7:751-759.
24. Tetley T.D. Macrophages and the pathogenesis of COPD. Chest 2002, 121:156S-159S.
25. Altiere R.J., Thompson D.C. Pulmonary physiology and pharmacology of the airways. Inhalation Aerosols: Physical and Biological Basis for Therapy 1996, 96-99.
26. El-Chemaly S., Pacheco-Rodriguez G., Ikeda Y., Malide D., Moss J. Lymphatics in idiopathic pulmonary fibrosis: new insights into an old disease. Lymphat Res Biol 2009, 7:197-203.
27. Cefalu W.T. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 2004, 27:239-246.
28. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002, 7:1184-1189.
29. Patton J.S., Bukar J.G., Eldon M.A. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004, 43:781-801.
30. Kling J. Inhaled insulin's last gasp?. Nat Biotechnol 2008, 26:479-480.
31. Neumiller J.J., Campbell R.K. Technosphere insulin: an inhaled prandial insulin product. BioDrugs 2010, 24:165-172.
32. Rossiter A., Howard C.P., Amin N., Costello D.J., Boss A.H. Technosphere® Insulin: Safety in Type 2 Diabetes Mellitus [abstract]. ADA Scientific Sessions 2010.
33. Balwani G. Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2B [abstract] 2003, Aradigm Corporation.
34. Walvoord E.C., de la P.A., Park S., Silverman B., Cuttler L., Rose S.R., et al. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety. J Clin Endocrinol Metab 2009, 94:2052-2059.
35. Dumont J.A., Bitonti A.J., Clark D., Evans S., Pickford M., Newman S.P. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 2005, 18:294-303.
36. Griesenbach U., Alton E.W. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 2009, 61:128-139.
37. Lam J.K., Liang W., Chan H.K. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev 2011.
38. http://www.cff.org/treatments/Pipeline.
39. Mansour H.M., Rhee Y.S., Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine 2009, 4:299-319.
40. Weers J., Metzheiser B., Taylor G., Warren S., Meers P., Perkins W.R. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 2009, 22:131-138.
41. Bruinenberg P., Serisier D., Cipolla D., Blanchard J. Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers and non-cystic bronchiectasis patients [abstract]. Am J Respir Crit Care Med 2010, 181.
42. Okusanya O.O., Bhavnani S.M., Hammel J., Minic P., Dupont L.J., Forrest A., et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009, 53:3847-3854.
43. Hinds W.C. Uniform Particle Motion. Aerosol Technology: Properties, Behavior and Measurement of Airborne Particles 1999, 53-55. Second ed.
44. Heyder J., Gebhart J., Rudolf G., Schiller C.F., Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15 [mu]m. J Aerosol Sci 1986, 17:811-825.
45. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release 2003, 86:131-144.
46. Tsapis N., Bennett D., Jackson B., Weitz D.A., Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 2002, 99:12001-12005.
47. Morawska L., Hofmann W., Hitchins-Loveday J., Swanson C., Mengersen K. Experimental study of the deposition of combustion aerosols in the human respiratory tract. J Aerosol Sci 2005, 36:939-957.
48. Geiser M., Casaulta M., Kupferschmid B., Schulz H., Semmler-Behnke M., Kreyling W. The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. Am J Respir Cell Mol Biol 2008, 38:371-376.
49. Semmler-Behnke M., Takenaka S., Fertsch S., Wenk A., Seitz J., Mayer P., et al. Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airways epithelium. Environ Health Perspect 2007, 115:728-733.
50. Takenaka S., Karg E., Kreyling W.G., Lentner B., Moller W., Behnke-Semmler M., et al. Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal Toxicol 2006, 18:733-740.
51. Furuyama A., Kanno S., Kobayashi T., Hirano S. Extrapulmonary translocation of intratracheally instilled fine and ultrafine particles via direct and alveolar macrophage-associated routes. Arch Toxicol 2009, 83:429-437.
52. Moller W., Felten K., Sommerer K., Scheuch G., Meyer G., Meyer P., et al. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am J Respir Crit Care Med 2008, 177:426-432.
53. Nag K., Vidyashankar S., Devraj R., Fritzen G.M., Panda A.K. Physicochemical studies on the interaction of serum albumin with pulmonary surfactant extract in films and bulk bilayer phase. J Colloid Interface Sci 2010, 352:456-464.
54. Lombry C., Edwards D.A., Preat V., Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol 2004, 286:L1002-L1008.
55. Patton J.S., McCabe J.G., Hansen S.E., Daugherty A.L. Absorption of human growth hormone from the rat lung. Biotechnol Ther 1989, 1:213-228.
56. Geiser M., Schurch S., Gehr P. Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer. J Appl Physiol 2003, 94:1793-1801.
57. Olmsted S.S., Padgett J.L., Yudin A.I., Whaley K.J., Moench T.R., Cone R.A. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001, 81:1930-1937.
58. Yudin A.I., Hanson F.W., Katz D.F. Human cervical mucus and its interaction with sperm: a fine-structural view. Biol Reprod 1989, 40:661-671.
59. Varum F.J., McConnell E.L., Sousa J.J., Veiga F., Basit A.W. Mucoadhesion and the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 2008, 25:207-258.
60. Lay J.C., Stang M.R., Fisher P.E., Yankaskas J.R., Bennett W.D. Airway retention of materials of different solubility following local intrabronchial deposition in dogs. J Aerosol Med 2003, 16:153-166.
61. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007, 104:1482-1487.
62. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl 2008, 47:9726-9729.
63. Ducreux J., Vanbever R. Crucial biopharmaceutical issues facing macromolecular candidates for inhalation: the role of macrophages in pulmonary protein clearance. Repiratory Drug Deliv Eur 2007, 31-41.
64. Luisetti M., Kadija Z., Mariani F., Rodi G., Campo I., Trapnell B.C. Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis 2010, 4:239-248.
65. Grainger C.I., Greenwell L.L., Martin G.P., Forbes B. The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. Eur J Pharm Biopharm 2009, 71:318-324.
66. Bur M., Huwer H., Lehr C.M., Hagen N., Guldbrandt M., Kim K.J., et al. Assessment of transport rates of proteins and peptides across primary human alveolar epithelial cell monolayers. Eur J Pharm Sci 2006, 28:196-203.
67. Patton J.S. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996, 19:3-36.
68. Codrons V., Vanderbist F., Ucakar B., Preat V., Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J Pharm Sci 2004, 93:1241-1252.
69. Sangwan S., Agosti J.M., Bauer L.A., Otulana B.A., Morishige R.J., Cipolla D.C., et al. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion. J Aerosol Med 2001, 14:185-195.
70. Qi Y., Zhao G., Liu D., Shriver Z., Sundaram M., Sengupta S., et al. Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route. Proc Natl Acad Sci USA 2004, 101:9867-9872.
71. Vanbever R. Performance-driven, pulmonary delivery of systemically acting drugs. Drug Discov Today Technol 2005, 2:39-46.
72. Yamahara H., Lehr C.M., Lee V., Kim K.J. Fate of insulin during transit across rat alveolar epithelial-cell monolayers. Eur J Pharm Biopharm Pharm 1994, 40:294-298.
73. Pang Y., Sakagami M., Byron P.R. The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. Eur J Pharm Sci 2005, 25:369-378.
74. Ikehata M., Yumoto R., Nakamura K., Nagai J., Takano M. Comparison of albumin uptake in rat alveolar type II and type I-like epithelial cells in primary culture. Pharm Res 2008, 25:913-922.
75. John T.A., Vogel S.M., Minshall R.D., Ridge K., Tiruppathi C., Malik A.B. Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung. J Physiol 2001, 533:547-559.
76. Kim K.J., Malik A.B. Protein transport across the lung epithelial barrier. Am J Physiol Lung Cell Mol Physiol 2003, 284:L247-L259.
77. Bitonti A.J., Dumont J.A. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev 2006, 58:1106-1118.
78. Matsukawa Y., Lee V.H., Crandall E.D., Kim K.J. Size-dependent dextran transport across rat alveolar epithelial cell monolayers. J Pharm Sci 1997, 86:305-309.
79. Choi H.S., Ashitate Y., Lee J.H., Kim S.H., Matsui A., Insin N., et al. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol 2010, 28:1300-1303.
80. Yacobi N.R., Demaio L., Xie J., Hamm-Alvarez S.F., Borok Z., Kim K.J., et al. Polystyrene nanoparticle trafficking across alveolar epithelium. Nanomedicine 2008, 4:139-145.
81. Yacobi N.R., Malmstadt N., Fazlollahi F., Demaio L., Marchelletta R., Hamm-Alvarez S.F., et al. Mechanisms of alveolar epithelial translocation of a defined population of nanoparticles. Am J Respir Cell Mol Biol 2010, 42:604-614.
82. Kemp S.J., Thorley A.J., Gorelik J., Seckl M.J., O'Hare M.J., Arcaro A., et al. Immortalization of human alveolar epithelial cells to investigate nanoparticle uptake. Am J Respir Cell Mol Biol 2008, 39:591-597.
83. Hastings R.H., Folkesson H.G., Matthay M.A. Mechanisms of alveolar protein clearance in the intact lung. Am J Physiol Lung Cell Mol Physiol 2004, 286:L679-L689.